This site is intended for Healthcare Professionals only

Numark criticises diclofenac switch

Numark criticises diclofenac switch

Numark says the reclassification of diclofenac tablets as a POM is a blow for pharmacy. Concerns over patient safety are paramount but diclofenac is an effective drug and part of pharmacists' OTC armoury for treating certain types of pain, says Mimi Lau, Numark's director of pharmacy services.

During last summer's consultation Numark had argued that diclofenac be kept as a P medicine but with stricter protocols. Similar parallels can be drawn here with pseudoephedrine, according to the company. There were concerns about this but it has remained as a P medicine with tighter controls over its sale.

Copy Link copy link button

Share:

Change privacy settings